Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study

Abstract

The need for maintenance therapy in patients with major depressive disorder (MDD) is underscored by the high likelihood of recurrence after short-term treatment. Current recommendations include treatment to remission and long-term treatment to prevent relapse and recurrence. This article will summarize the design and results of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study, which have been published elsewhere. PREVENT evaluated venlafaxine extended release (ER) versus placebo in two 1-year maintenance phases for prevention of recurrence in patients with MDD who responded to acute and continuation therapy. Venlafaxine ER was effective in preventing long-term recurrence when compared with placebo, with a significant reduction in likelihood of recurrence and significantly longer time to recurrence after both 1 and 2 years of maintenance therapy. Recurrence rates in the first and second maintenance periods for patients receiving placebo were similar (42 vs 45%), but recurrence rates for patients receiving venlafaxine ER decreased dramatically (23 vs 8%). The PREVENT study adds to current understanding regarding the benefits of long-term antidepressant therapy in preventing recurrence.

Keywords::

• antidepressant
• depression
• fluoxetine
• maintenance
• PREVENT
• recurrence
• venlafaxine

Financial and competing interests disclosure

The PREVENT study was conducted with funding from Wyeth Research.

Susan G Kornstein has received grants/research from Department of Health and Human Services, National Institute of Mental Health, Bristol-Myers Squibb Company, Lilly, Inc., Forest Laboratories, Inc., Wyeth, Inc., Novartis Pharmaceuticals, Inc., Sepracor, Inc., Boehringer-Ingelheim, Sanofi-Synthelabo, Astra-Zeneca, Pfizer, GlaxoSmithKline, Mitsubishi-Tokyo, Merck, Biovail, and Berlex. She has been on the Advisory Board or received honoraria from Wyeth, Inc., Pfizer, Inc., Biovail, Inc., Lilly, Inc., Bristol-Myers Squibb Company, Forest Laboratories, Neurocrine, Sepracor, Inc., Berlex and Warner-Chilcott. Susan G Kornstein has also received book royalties from Guilford Press.

The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Assistance with manuscript development was provided by Una A Kistner, RPh, on behalf of Advogent.